Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Philip S Wells, MD
Ottawa Hospital Research Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Capital Health District Authority
Halifax, Nova Scotia, Canada
- Hamilton Health Sciences
Hamilton, Ontario, Canada
- London Health Science Centre
London, Ontario, Canada
- the Ottawa Hospital
Ottawa, Ontario, Canada
- Chum-Notre-Dame Hospital
Montreal, Quebec, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2012
- Primary completion
- 31 Oct 2016
- Completion
- 31 Oct 2016
- Last update posted
- 11 May 2017
- Registered enrollment
- 700
- Registry id
- NCT01602445
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.